Skip to main content
Orexo logo

Orexo — Investor Relations & Filings

Ticker · ORX ISIN · SE0000736415 LEI · 549300LJ5CCWDPTK9Z08 ST Manufacturing
Open in API
Filings indexed 841 across all filing types
Latest filing 2013-10-23 Interim / Quarterly Rep…
Country SE Sweden
Listing ST ORX

About Orexo

https://orexo.com/

Orexo is a commercial-stage pharmaceutical company focused on developing improved pharmaceuticals and digital therapies. The company addresses unmet patient needs, particularly within substance use disorders and mental health. It leverages proprietary drug delivery and formulation technologies to create innovative treatment solutions. Orexo's activities span research, development, and commercialization of its products.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2013
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Delårsrapport januari-september 2013' (Interim Report January-September 2013). It contains comprehensive financial statements, including income statements, cash flow data, and detailed management commentary on business operations, product launches (Zubsolv, Abstral), and market performance. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. 9M 2013
2013-10-23 Swedish
Interim / Quarterly Report 2013
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Interim report January-September 2013' and contains comprehensive financial statements, including income statements, cash flow data, and detailed management commentary on operations, product launches (Zubsolv, Abstral), and financial guidance. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. 9M 2013
2013-10-23 English
Orexo utser valberedning och offentliggör finansiell kalender 2013/2014
AGM Information Classification · 1% confidence The document is a press release dated October 15, 2013, titled "Orexo appoints nomination committee and publishes financial calendar 2013/2014". It details the composition of the nomination committee for the 2014 Annual General Meeting (AGM) and provides a schedule of future financial events, including the date for the 2014 AGM and the release of the Annual Report (Årsredovisningen). Since the document's primary function is to announce the formation of the nomination committee (related to AGM governance) and publish a schedule of future reports/meetings, it is not the full AGM material (AGM-R), the full Annual Report (10-K), or a specific report itself. The announcement of the AGM date and the nomination committee structure strongly points towards governance or meeting-related announcements. Given the content focuses on the nomination committee and the schedule for the upcoming AGM, it relates closely to the preparation for the Annual General Meeting. However, it is not the AGM presentation itself (AGM-R) nor the proxy materials (PSI). It is an announcement of governance structure setup and a financial calendar. This type of announcement, which sets the stage for the AGM and reports, fits best under the general category of Regulatory Filings (RNS) or potentially Governance Information (CGR) due to the nomination committee. Since it explicitly publishes the financial calendar, which includes the date for the Annual Report release, and the document is short and serves as an announcement, RNS is the most appropriate fallback for a general corporate announcement that doesn't fit a more specific category like DIV or ER. However, the focus on the nomination committee (Valberedning) and the AGM date suggests a strong link to AGM preparation. Since there isn't a specific code for 'AGM Announcement', and it's not the AGM presentation itself, RNS is the safest classification, although it contains elements related to AGM preparation.
2013-10-15 Swedish
Orexo appoints Nomination Committee and publishes financial calendar 2013/2014
AGM Information Classification · 1% confidence The document is a press release dated October 15, 2013. The primary content announces the appointment of a Nomination Committee ahead of the Annual General Meeting (AGM) 2014 and publishes the financial calendar for 2013/2014, including the date for the AGM itself (April 15, 2014). While it mentions the AGM, it is not the presentation materials (AGM-R) or the proxy statement (PSI). It is an announcement regarding corporate governance structure (Nomination Committee) and future reporting dates. Since it deals with the composition of the committee responsible for proposing board members and fees, it touches upon Governance (CGR). However, the most specific action announced is the publication of the financial calendar and the announcement of the AGM date, which often accompanies other corporate updates. Given the focus on the Nomination Committee appointment and the publication of the financial calendar, this is best classified as a general corporate announcement. Since it is not a specific report (like 10-K, ER, IR) but a general update on corporate structure and future dates, and it doesn't fit perfectly into MANG (management change) or DVA (voting results), the most appropriate category is the general regulatory/corporate announcement fallback, RNS, or potentially CGR due to the Nomination Committee focus. Given the dual nature (Governance structure update + Calendar publication), and the short length (3394 chars) suggesting it's an announcement rather than a full report, RNS is a safe fallback, but CGR (Governance Information) is also highly relevant due to the Nomination Committee details. I will lean towards CGR as the Nomination Committee is a core governance body, and the announcement details its composition and function.
2013-10-15 English
Antal aktier och röster i Orexo
Share Issue/Capital Change Classification · 1% confidence The document is a short press release dated September 30, 2013, titled "Antal aktier och röster i Orexo" (Number of shares and votes in Orexo). It explicitly states that the number of shares and votes has changed due to the exercise of stock options, resulting in a new total share count (32,674,441). This type of announcement, detailing a change in the total number of outstanding shares, directly relates to capital structure changes or share issuance. Among the provided definitions, 'Share Issue/Capital Change' (SHA) is the most appropriate fit, as the change stems from the exercise of options, effectively increasing the share count. It is not a general regulatory filing (RNS) because it fits a specific category, nor is it a dividend notice (DIV) or director dealing (DIRS).
2013-09-30 Swedish
Number of shares and votes in Orexo
Share Issue/Capital Change Classification · 1% confidence The document is a short press release dated September 30, 2013, announcing a change in the total number of shares and votes in Orexo AB due to the exercise of warrants. This directly relates to a change in the company's capital structure or share count. Reviewing the definitions, 'Share Issue/Capital Change' (SHA) covers announcements regarding new share issues or capital changes. Although the document mentions warrants being exercised (which leads to new shares), it is a specific notification about the resulting share count. It is not a general financing update (CAP) or a transaction in own shares (POS, which usually implies buybacks/sales by the company itself). Since it is a direct notification about the total number of shares outstanding following an event, SHA is the most appropriate classification. The document length is short (1600 chars), but it contains the core information rather than just announcing another report, so the RPA/RNS rule does not strictly apply here as the content itself is the required disclosure.
2013-09-30 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.